KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Evolent Health (EVH) EBITDA (2016 - 2025)

Evolent Health has reported EBITDA over the past 11 years, most recently at -$429.4 million for Q4 2025.

  • Quarterly results put EBITDA at -$429.4 million for Q4 2025, down 1285.05% from a year ago — trailing twelve months through Dec 2025 was -$580.3 million (down 517.64% YoY), and the annual figure for FY2025 was -$580.3 million, down 517.64%.
  • EBITDA for Q4 2025 was -$429.4 million at Evolent Health, down from -$27.6 million in the prior quarter.
  • Over the last five years, EBITDA for EVH hit a ceiling of $1.9 million in Q3 2022 and a floor of -$429.4 million in Q4 2025.
  • Median EBITDA over the past 5 years was -$25.7 million (2023), compared with a mean of -$43.7 million.
  • Biggest five-year swings in EBITDA: soared 114.28% in 2022 and later tumbled 1891.89% in 2023.
  • Evolent Health's EBITDA stood at -$5.6 million in 2021, then crashed by 103.38% to -$11.5 million in 2022, then plummeted by 260.42% to -$41.4 million in 2023, then increased by 25.09% to -$31.0 million in 2024, then plummeted by 1285.05% to -$429.4 million in 2025.
  • The last three reported values for EBITDA were -$429.4 million (Q4 2025), -$27.6 million (Q3 2025), and -$51.1 million (Q2 2025) per Business Quant data.